Ji 2022 - High-Dose Mazdutide in Chinese Adults With Obesity

EClinicalMedicine·November 1, 2022

Linong Ji

Summary

High-dose mazdutide showed promising 12-week body-weight loss and supported later phase 2 obesity development.

Study Details

Study Design

Randomized, double-blind, placebo-controlled phase 1b/2a clinical study

Indication

Moderate-to-severe obesity

Intervention

High-dose mazdutide / IBI362 vs placebo

Species

Human

Risk of Bias Assessment

Early-stage trial; sponsor-funded